De Petrocellis Luciano, Schiano Moriello Aniello, Byun Joon Seok, Sohn Joo Mi, Lee Jae Yeol, Vázquez-Romero Ana, Garrido Maria, Messeguer Angel, Zhang Fang-Xiong, Zamponi Gerald W, Deplano Alessandro, Congiu Cenzo, Onnis Valentina, Balboni Gianfranco, Di Marzo Vincenzo
Endocannabinoid Research Group, Institute of Biomolecular Chemistry, National Research Council, Via Campi Flegrei 34, Comprensorio Olivetti, 80078 Pozzuoli, Naples, Italy.
Endocannabinoid Research Group, Institute of Biomolecular Chemistry, National Research Council, Via Campi Flegrei 34, Comprensorio Olivetti, 80078 Pozzuoli, Naples, Italy.
Pharmacol Res. 2015 Sep;99:362-9. doi: 10.1016/j.phrs.2015.07.009. Epub 2015 Jul 17.
Four positively charged compounds, previously shown to produce analgesic activity by interacting with prokineticin receptor or T-type calcium channels, were tested for their ability to inhibit capsaicin-induced elevation of intracellular Ca(2+) in HEK-293 cells stably transfected with the human recombinant TRPV1, with the goal of identifying novel TRPV1 open-pore inhibitors. KYS-05090 showed the highest potency as a TRPV1 antagonist, even higher than that of the open-pore triazine inhibitor 8aA. The latter showed quite remarkable agonist/desensitizer activity at the rat recombinant TRPM8 channel. The activity of KYS-05090 and the other compounds was selective because none of these compounds was able to modulate the rat TRPA1 channel. Open-pore inhibitors of TRPV1 may be a new class of multi-target analgesics with lesser side effects, such as loss of acute pain sensitivity and hyperthermia, than most TRPV1 antagonists developed so far.
四种带正电荷的化合物,先前已证明它们通过与促动力蛋白受体或T型钙通道相互作用产生镇痛活性,此次对它们抑制辣椒素诱导的稳定转染人重组TRPV1的HEK - 293细胞内Ca(2+)升高的能力进行了测试,目的是鉴定新型TRPV1开孔抑制剂。KYS - 05090作为TRPV1拮抗剂表现出最高的效力,甚至高于开孔三嗪抑制剂8aA。后者在大鼠重组TRPM8通道上表现出相当显著的激动剂/脱敏剂活性。KYS - 05090和其他化合物的活性具有选择性,因为这些化合物均不能调节大鼠TRPA1通道。TRPV1的开孔抑制剂可能是一类新型的多靶点镇痛药,与目前开发的大多数TRPV1拮抗剂相比,副作用较小,如急性疼痛敏感性丧失和体温过高。